• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Italy·Healthcare·ARBS.MI
Share

Arterra Bioscience S.p.A. Stocks

€ 3Last Updated 09.11.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

€ 21.91M

€ 3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Arterra Bioscience S.p.A. is a biotechnology company fundamentally driven by scientific research, concentrating on the discovery and development of a wide range of ingredients and nature-based solutions. The firm's activities encompass the creation of advanced technological frameworks, innovative extraction methodologies, and foundational raw materials, specifically tailored for the beauty, agricultural, and nutritional supplement sectors. Established in 2003, Arterra Bioscience S.p.A. is headquartered in Naples, Italy.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.11.2026 21:19

Analysts have begun lowering their price targets for Nvidia. Without Huang, the company could lose up to 30% of its value.

10.11.2026 19:53

U.S. stocks opened lower due to high inflation and expectations of a rate hike

10.11.2026 19:31

Shareholders have filed a lawsuit against Nvidia and Huang. What risks does the “key person” risk pose to the company?

10.11.2026 18:41

Inflation in the U.S. rose more than expected in October. What decision can we expect from the Fed?

10.11.2026 18:14

Investors have flocked to defensive stocks out of fear that the AI rally is coming to an end. Will this last?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026